United States-based Amgen (NASDAQ: AMGN) yesterday reported its financial results for the second quarter of 2019.

The company reported total revenues of USD5.9bn in the second quarter of 2019, down 3% compared to the second quarter of 2018.

The firm posted USD1.3bn of free cash flow in the second quarter of 2019 compared with USD1.9bn in the year-ago period. GAAP earnings per share (EPS) increased 3% to USD3.57 benefited by lower weighted-average shares outstanding.

Robert A Bradway, chairman and chief executive officer, said, 'With our newer products generating strong volume gains globally and many first-in-class medicines advancing through our pipeline, we are well positioned to serve patients and deliver long-term growth for our shareholders.'